melatonin has been researched along with Recrudescence in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial is an unicenter, prospective, randomized, double-blind, placebo-controlled, phase 2 study of the intravenous administration of melatonin." | 9.12 | A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with An ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, MJ; Jimenez-Sosa, A; Kaski, JC; Reiter, RJ, 2007) |
| "Several experimental studies have shown that melatonin has an oncostatic action, either by stimulating host antitumor immune defenses or by directly inhibiting the growth of some cancer histotypes, including melanoma." | 9.08 | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. ( Barni, S; Brivio, F; Brivio, O; Crippa, D; Lissoni, P; Meregalli, S; Tancini, G, 1996) |
| "Treatment with melatonin ameliorates disease in an experimental model of multiple sclerosis and directly interferes with the differentiation of human and mouse T cells." | 5.42 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. ( Balbuena Aguirre, ME; Correale, J; Farez, MF; Garo, LP; Kuchroo, VK; Mascanfroni, ID; Méndez-Huergo, SP; Murugaiyan, G; Patel, B; Quintana, FJ; Rabinovich, GA; Yeste, A; Ysrraelit, MC; Zhu, C, 2015) |
| "Melatonin is a hormone that is influenced by the circadian environmental variations of dark-light and is a modulator of the immune system." | 5.30 | Melatonin restores and enhances the human type B tonsillar lymphocyte subset in recurrent acute tonsillitis. ( Delgado, F; Guerrero, JM; Lopez-Gonzalez, MA; Sanchez, B, 1998) |
| "The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial is an unicenter, prospective, randomized, double-blind, placebo-controlled, phase 2 study of the intravenous administration of melatonin." | 5.12 | A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with An ( Abreu-Gonzalez, P; Dominguez-Rodriguez, A; Garcia-Gonzalez, MJ; Jimenez-Sosa, A; Kaski, JC; Reiter, RJ, 2007) |
| "Several experimental studies have shown that melatonin has an oncostatic action, either by stimulating host antitumor immune defenses or by directly inhibiting the growth of some cancer histotypes, including melanoma." | 5.08 | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. ( Barni, S; Brivio, F; Brivio, O; Crippa, D; Lissoni, P; Meregalli, S; Tancini, G, 1996) |
| "(1) When an antidepressant is considered a necessary addition to psychological support in treating patients with depression, the first-line drug is a tricyclic such as clomipramine or a selective serotonin reuptake inhibitor (SSRI) such as paroxetine; (2) Agomelatine, a melatonin receptor agonist, is approved in the European Union for the treatment of depression; (3) Available evaluation does not include any clinical trials designed to compare the efficacy of agomelatine with that of a tricyclic or a selective serotonin reuptake inhibitor." | 3.75 | Agomelatine: new drug. Adverse effects and no proven efficacy. ( , 2009) |
| "A haloperidol-treated patient with chronic schizophrenia had a near-arrhythmic circadian rest-activity cycle, whereas rhythms of 6-sulphatoxy-melatonin and core body temperature were of normal amplitude and phase-advanced." | 3.69 | A schizophrenic patient with an arrhythmic circadian rest-activity cycle. ( Cajochen, C; Nussbaum, P; Wirz-Justice, A, 1997) |
| "Melatonin (MLT) is a main synchronizer of the sleep/wake cycle, playing a role of transduction to brain functioning of informations about periodical environmental changes, i." | 2.69 | Melatonin add-on in manic patients with treatment resistant insomnia. ( Bersani, G; Garavini, A, 2000) |
| "Melatonin is a hormone involved in the entrainment of circadian rhythms, which appears dysregulated in drug users." | 1.46 | Melatonin reduces motivation for cocaine self-administration and prevents relapse-like behavior in rats. ( Spanagel, R; Takahashi, TT; Vengeliene, V, 2017) |
| "Rebound insomnia, defined as a one-point deterioration in sleep quality below baseline values, was found in 3." | 1.42 | Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. ( Hajak, G; Lemme, K; Zisapel, N, 2015) |
| "Melatonin is an endogenous synchronizer of biological rhythms and a modulator of physiological functions and behaviors of all mammals." | 1.42 | Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption. ( Noori, HR; Spanagel, R; Vengeliene, V, 2015) |
| "Treatment with melatonin ameliorates disease in an experimental model of multiple sclerosis and directly interferes with the differentiation of human and mouse T cells." | 1.42 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. ( Balbuena Aguirre, ME; Correale, J; Farez, MF; Garo, LP; Kuchroo, VK; Mascanfroni, ID; Méndez-Huergo, SP; Murugaiyan, G; Patel, B; Quintana, FJ; Rabinovich, GA; Yeste, A; Ysrraelit, MC; Zhu, C, 2015) |
| "Recurrent hypersomnia is characterized by recurring episodes of hypersomnia of 18 h or more per day lasting from several days to several weeks." | 1.32 | Case study: differences in human Per2 gene expression, body temperature, cortisol, and melatonin parameters in remission and hypersomnia in a patient with recurrent hypersomnia. ( Hamada, A; Joudoi, T; Kawatani, J; Miike, T; Ohmura, T; Tomoda, A; Tonooka, S, 2003) |
| "A hypnic headache was captured in one patient arising out of rapid eye movement sleep at a time of severe oxygen desaturation." | 1.31 | Polysomnography in hypnic headache syndrome. ( Dodick, DW, 2000) |
| "Melatonin is a hormone that is influenced by the circadian environmental variations of dark-light and is a modulator of the immune system." | 1.30 | Melatonin restores and enhances the human type B tonsillar lymphocyte subset in recurrent acute tonsillitis. ( Delgado, F; Guerrero, JM; Lopez-Gonzalez, MA; Sanchez, B, 1998) |
| "Treatment with cyproheptadine produced improvement of symptoms in 76% of cases." | 1.30 | Characterisation of headshaking syndrome--31 cases. ( Bell, SA; Madigan, JE, 1998) |
| "The occurrence of migraine headaches in patients with multiple sclerosis (MS) has been recognized for quite some time but the significance of this association to the pathogenesis of MS largely has been ignored." | 1.29 | The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link. ( Awerbuch, GI; Sandyk, R, 1994) |
| "Heme arginate treatment promptly decreased total tryptophan levels (from 69 +/- 9, to 44 +/- 5, mean +/- SEM, mumole/l, p < 0." | 1.29 | Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. ( Baudry, P; Callebert, J; Deybach, JC; Nordmann, Y; Puy, H; Touitou, Y, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 9 (36.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajak, G | 1 |
| Lemme, K | 1 |
| Zisapel, N | 1 |
| Parekh, PJ | 1 |
| Oldfield Iv, EC | 1 |
| Challapallisri, V | 1 |
| Ware, JC | 1 |
| Johnson, DA | 1 |
| Yang, GH | 1 |
| Li, YC | 1 |
| Wang, ZQ | 1 |
| Liu, B | 1 |
| Ye, W | 1 |
| Ni, L | 1 |
| Zeng, R | 1 |
| Miao, SY | 1 |
| Wang, LF | 1 |
| Liu, CW | 1 |
| Vengeliene, V | 2 |
| Noori, HR | 1 |
| Spanagel, R | 2 |
| Farez, MF | 1 |
| Mascanfroni, ID | 1 |
| Méndez-Huergo, SP | 1 |
| Yeste, A | 1 |
| Murugaiyan, G | 1 |
| Garo, LP | 1 |
| Balbuena Aguirre, ME | 1 |
| Patel, B | 1 |
| Ysrraelit, MC | 1 |
| Zhu, C | 1 |
| Kuchroo, VK | 1 |
| Rabinovich, GA | 1 |
| Quintana, FJ | 1 |
| Correale, J | 1 |
| Takahashi, TT | 1 |
| Vanelle, JM | 1 |
| Tomoda, A | 1 |
| Joudoi, T | 1 |
| Kawatani, J | 1 |
| Ohmura, T | 1 |
| Hamada, A | 1 |
| Tonooka, S | 1 |
| Miike, T | 1 |
| Dominguez-Rodriguez, A | 1 |
| Abreu-Gonzalez, P | 1 |
| Garcia-Gonzalez, MJ | 1 |
| Kaski, JC | 1 |
| Reiter, RJ | 1 |
| Jimenez-Sosa, A | 1 |
| Sandyk, R | 2 |
| Awerbuch, GI | 2 |
| Puy, H | 1 |
| Deybach, JC | 1 |
| Baudry, P | 1 |
| Callebert, J | 1 |
| Touitou, Y | 1 |
| Nordmann, Y | 1 |
| Lissoni, P | 1 |
| Brivio, O | 1 |
| Brivio, F | 1 |
| Barni, S | 1 |
| Tancini, G | 1 |
| Crippa, D | 1 |
| Meregalli, S | 1 |
| Wirz-Justice, A | 1 |
| Cajochen, C | 1 |
| Nussbaum, P | 1 |
| Lopez-Gonzalez, MA | 1 |
| Guerrero, JM | 1 |
| Sanchez, B | 1 |
| Delgado, F | 1 |
| Madigan, JE | 1 |
| Bell, SA | 1 |
| Katz, G | 1 |
| Durst, R | 1 |
| Barel, YC | 1 |
| Knobler, HY | 1 |
| Bersani, G | 1 |
| Garavini, A | 1 |
| Dodick, DW | 1 |
| Grunhaus, L | 1 |
| Hirschman, S | 1 |
| Dolberg, OT | 1 |
| Schreiber, S | 1 |
| Dannon, PN | 1 |
| Peres, MF | 1 |
| Stiles, MA | 1 |
| Oshinsky, M | 1 |
| Rozen, TD | 1 |
| Lesur, A | 1 |
| Blehar, MC | 1 |
| Rosenthal, NE | 1 |
| Kennedy, SH | 1 |
| Tighe, S | 1 |
| McVey, G | 1 |
| Brown, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Protective Effect of Melatonin on Smoke-induced Vascular Injury in Human[NCT02591238] | Phase 4 | 68 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Melatonin as an Adjunct in Patients With Acute myocaRdial Infarction Undergoing Primary Angioplasty[NCT00640094] | Phase 2 | 272 participants (Actual) | Interventional | 2013-05-31 | Terminated | ||
| Effects of Melatonin on Reperfusion Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT03303378] | 190 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02591238)
Timeframe: Three months
| Intervention | g/L (Mean) |
|---|---|
| IV Non-smoker + Placebo | 2.76 |
| III Non-smoker + Melatonin | 2.38 |
| II Smoker + Placebo | 2.89 |
| I Smoker + Melatonin | 2.49 |
(NCT02591238)
Timeframe: Three months.
| Intervention | umol/L (Mean) |
|---|---|
| IV Non-smoker + Placebo | 389 |
| III Non-smoker + Melatonin | 382 |
| II Smoker + Placebo | 499 |
| I Smoker + Melatonin | 425 |
(NCT02591238)
Timeframe: Three months.
| Intervention | mmol/L (Mean) |
|---|---|
| IV Non-smoker + Placebo | 4.4 |
| III Non-smoker + Melatonin | 4.24 |
| II Smoker + Placebo | 5.02 |
| I Smoker + Melatonin | 4.79 |
(NCT02591238)
Timeframe: Three months.
| Intervention | mmol/L (Mean) |
|---|---|
| IV Non-smoker + Placebo | 1.85 |
| III Non-smoker + Melatonin | 1.95 |
| II Smoker + Placebo | 2.2 |
| I Smoker + Melatonin | 2.19 |
(NCT02591238)
Timeframe: Three months.
| Intervention | mmol/L (Mean) |
|---|---|
| IV Non-smoker + Placebo | 4.51 |
| III Non-smoker + Melatonin | 4.5 |
| II Smoker + Placebo | 4.74 |
| I Smoker + Melatonin | 4.45 |
(NCT02591238)
Timeframe: Three months.
| Intervention | mmol/L (Mean) |
|---|---|
| IV Non-smoker + Placebo | 1.21 |
| III Non-smoker + Melatonin | 1.23 |
| II Smoker + Placebo | 1.42 |
| I Smoker + Melatonin | 1.41 |
2 reviews available for melatonin and Recrudescence
| Article | Year |
|---|---|
[Schizophrenia and circadian rhythms].
Topics: Acute Disease; Antipsychotic Agents; Circadian Rhythm; Humans; Melatonin; Recurrence; Schizophrenia; | 2009 |
Seasonal affective disorders and phototherapy. Report of a National Institute of Mental Health-sponsored workshop.
Topics: Animals; Depressive Disorder; Humans; Melatonin; National Institute of Mental Health (U.S.); Phototh | 1989 |
4 trials available for melatonin and Recrudescence
19 other studies available for melatonin and Recrudescence
| Article | Year |
|---|---|
Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin.
Topics: Aged; Delayed-Action Preparations; Female; Germany; Humans; Hypnotics and Sedatives; Male; Melatonin | 2015 |
Sleep disorders and inflammatory disease activity: chicken or the egg?
Topics: Animals; C-Reactive Protein; Circadian Rhythm; Clinical Trials as Topic; Colitis, Ulcerative; Crohn | 2015 |
Protective effect of melatonin on cigarette smoke-induced restenosis in rat carotid arteries after balloon injury.
Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Blotting, Western; Carotid Arteries; Caroti | 2014 |
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Aminopyridines; Animals | 2015 |
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; CCAAT-Enhancer-Binding Proteins; Cell Different | 2015 |
Melatonin reduces motivation for cocaine self-administration and prevents relapse-like behavior in rats.
Topics: Animals; Behavior, Addictive; Behavior, Animal; Cocaine; Dose-Response Relationship, Drug; Extinctio | 2017 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexano | 2009 |
Case study: differences in human Per2 gene expression, body temperature, cortisol, and melatonin parameters in remission and hypersomnia in a patient with recurrent hypersomnia.
Topics: Adolescent; Body Temperature; Circadian Rhythm; Disorders of Excessive Somnolence; Gene Expression; | 2003 |
The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link.
Topics: Adult; Aged; Blood-Brain Barrier; Brain; Calcinosis; Female; Humans; Melatonin; Methylprednisolone; | 1994 |
Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis.
Topics: Adult; Age of Onset; Aged; Female; Humans; Male; Melatonin; Middle Aged; Multiple Sclerosis; Pineal | 1994 |
Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks.
Topics: Adult; Arginine; Circadian Rhythm; Female; Heme; Humans; Melatonin; Porphyria, Acute Intermittent; R | 1993 |
A schizophrenic patient with an arrhythmic circadian rest-activity cycle.
Topics: Adult; Antipsychotic Agents; Bed Rest; Body Temperature; Catatonia; Chronic Disease; Circadian Rhyth | 1997 |
Melatonin restores and enhances the human type B tonsillar lymphocyte subset in recurrent acute tonsillitis.
Topics: Acute Disease; Adolescent; B-Lymphocyte Subsets; Cells, Cultured; Child; Child, Preschool; Female; H | 1998 |
Characterisation of headshaking syndrome--31 cases.
Topics: Animals; Antioxidants; Behavior, Animal; Cyproheptadine; Female; Horses; Male; Melatonin; Recurrence | 1998 |
De novo jet-lag psychosis.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clopenthixol; Female; Humans; Jet Lag Syndrome; Ma | 1999 |
Polysomnography in hypnic headache syndrome.
Topics: Aged; Female; Headache; Humans; Indomethacin; Male; Melatonin; Middle Aged; Polysomnography; Recurre | 2000 |
Remitting form of hemicrania continua with seasonal pattern.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Headache Disorders; Humans; Indomethacin; Melatonin | 2001 |
[Phototherapy in depression].
Topics: Depression; Female; Humans; Melatonin; Phototherapy; Recurrence; Seasons | 1990 |
Melatonin and cortisol "switches" during mania, depression, and euthymia in a drug-free bipolar patient.
Topics: Adult; Bipolar Disorder; Blood Specimen Collection; Circadian Rhythm; Depressive Disorder; Evaluatio | 1989 |